乌帕替尼治疗非生物制剂应答不足的银屑病关节炎:SELECT-PsA 1 研究 56 周数据
SELECT-PsA 1 是一项随机双盲 3 期研究,在非生物制剂应答不足的银屑病关节炎患者中比较乌帕替尼 15 mg、30 mg 与安慰剂及阿达木单抗。56 周数据显示乌帕替尼疗效维持,ACR、PASI、MDA 应答通常数值上高于阿达木单抗,未发现新安全性信号。
要点
- 乌帕替尼 15 mg 和 30 mg 至 56 周维持疗效,ACR20/50/70、PASI75/90/100 和 MDA 应答通常数值上高于阿达木单抗。
- 安慰剂组切换至乌帕替尼后第 56 周改善与初始随机接受乌帕替尼者相当。
- 严重不良事件率:乌帕替尼 15 mg 为 9.1 事件/100 患者年,30 mg 为 12.3 事件/100 患者年;每组各有 2 例死亡。
核心结论
- 乌帕替尼 15 mg 和 30 mg 至 56 周维持银屑病关节炎多领域疗效,未观察到新的安全性信号。
研究设计与样本
- SELECT-PsA 1 为随机双盲 3 期研究,患者接受乌帕替尼 15 mg 或 30 mg 每日一次、阿达木单抗 40 mg 隔周一次至 56 周,或安慰剂至 24 周后切换至乌帕替尼 15 mg 或 30 mg 至 56 周。
主要发现
- 与 24 周结果一致,ACR20/50/70、PASI75/90/100 和 MDA 应答至 56 周维持,且通常数值上高于阿达木单抗。
- 影像学进展抑制也维持;安慰剂切换至乌帕替尼的患者第 56 周改善与初始随机接受乌帕替尼者相当。
- 严重不良事件率:乌帕替尼 15 mg 为 9.1 事件/100 患者年,30 mg 为 12.3 事件/100 患者年。
- 乌帕替尼 15 mg 组和 30 mg 组各报告 2 例死亡。
关键数值与推荐
- 疗效终点包括 ACR20/50/70、PASI75/90/100、MDA 及改良 Sharp/van der Heijde 评分较基线变化。
- 安全性以每 100 患者年的治疗中出现的不良事件总结。
临床怎么用
- 对非生物制剂应答不足的银屑病关节炎患者,乌帕替尼 15 mg 或 30 mg 至 56 周可维持多领域疗效。
- 临床使用中需关注严重不良事件,乌帕替尼 30 mg 的严重不良事件率数值上高于 15 mg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of Rheumatology (ACR) criteria at 12 weeks in patients with psoriatic arthritis (PsA). Here, we report 56-week efficacy and safety in patients from SELECT-PsA 1. METHODS: Patients received upadacitinib 15 mg or 30 mg once daily, adalimumab 40 mg every other week for 56 weeks or placebo through week 24 switched thereafter to upadacitinib 15 mg or 30 mg until week 56. Efficacy endpoints included the proportion of patients achieving ≥20%/50%/70% improvement in ACR criteria (ACR20/50/70), ≥75%/90%/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100), minimal disease activity (MDA) and change from baseline in modified total Sharp/van der Heijde Score. Treatment-emergent adverse events per 100 patient years (PY) were summarised. RESULTS: Consistent with results through week 24, ACR20/50/70, PASI75/90/100 and MDA responses were maintained with upadacitinib through week 56 and were generally numerically higher than with adalimumab; inhibition of radiographic progression was also maintained. Patients who switched from placebo to upadacitinib exhibited comparable improvements at week 56 as patients originally randomised to upadacitinib. The rates of serious adverse events were 9.1 events/100 PY with upadacitinib 15 mg and 12.3 events/100 PY with upadacitinib 30 mg. Two deaths were reported in each of the upadacitinib groups. CONCLUSION: Efficacy across various domains of PsA were maintained with upadacitinib 15 mg and 30 mg through week 56 with no new safety signals observed.
引用
- McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021. PMID: 34663636. doi:10.1136/rmdopen-2021-001838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。